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Abstract
Background: Guidelines recommend Irritable Bowel Syndrome (IBS) diagnosis and management in primary care with
minimal investigations; however little evidence exists regarding risk of organic gastrointestinal conditions following
diagnosis of IBS and how such risks vary over the long term. This study assesses excess incidence of coeliac disease,
inflammatory bowel disease (IBD) and colorectal cancer (CRC) and variation with age and time after IBS diagnosis.
Methods: IBS patients and controls were identified within the UK Clinical Practice Research Dataset. Incidence rates were
calculated and stratified by age and time since IBS diagnosis with incident rate ratios generated.
Results: Fifteen years after IBS diagnosis there is a significant cumulative excess incidence of coeliac disease, IBD and CRC in
IBS of 3.7% compared to 1.7% in controls. For every 10000 patient years, IBS patients experienced an additional 4 diagnoses
of coeliac disease, 13 of IBD and 4 CRCs. In each condition peak excess incidence was in the 6 months following diagnosis.
After one year, increased incidence of coeliac disease remained consistent without variation by age. IBD incidence fell
slowly, with higher rates in those under 30. CRC incidence was increased only in patients aged 30 to 74 during the first 5
years.
Conclusion: Some IBS patients later receive organic gastrointestinal diagnoses, with the early excess incidence likely
detected during diagnostic investigation at the time of IBS diagnosis. More than 5 years after IBS diagnosis there is no
increased risk of CRC compared to the general population, but a small excess risk of coeliac disease and IBD persists. Overall,
though our findings provide reassurance that non-specialists, especially those in primary care, are unlikely to be missing an
organic condition in the majority of their patients. This suggests that current guidelines suggesting avoidance of universal
referral for these patients are appropriate.
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Introduction
Irritable bowel syndrome (IBS) is a chronic functional condition
affecting about 11% of the global population [1]. It is clinically
heterogeneous and patients present with various combinations of
abdominal pain, altered bowel habit and bloating, but there is no
biomarker or unifying structural abnormality to allow definitive
diagnosis. Consequently diagnostic criteria have been developed to
enable diagnosis based on symptom profile. Current international
consensus criteria (Rome III) recommend diagnosing IBS without
extensive investigations to exclude other conditions [2]. Alongside
these recommendations, there is increasing emphasis on diagnos-
ing and managing IBS within primary care [3,4].
Despite this, 10–50% [5–7] of patients with IBS are referred to
secondary care, with many gastroenterologists and generalists still
considering IBS a diagnosis of exclusion [8]. Some referrals are
due to concern about organic conditions that share similar
symptomatology [7,8], such as cholecystitis, pancreatic insufficien-
cy, endometriosis, lactose intolerance, bile acid malabsorbtion and
small bowel bacterial overgrowth. Three conditions of particular
interest are coeliac disease, inflammatory bowel disease (IBD) and
colorectal cancer (CRC). Currently little is known about the
PLOS ONE | www.plosone.org 1 September 2014 | Volume 9 | Issue 9 | e106478
likelihood of a patient having one of these conditions if they have
symptoms that suggest IBS [9]. Even less is known about the risk of
patients subsequently being diagnosed with these conditions after
being diagnosed with IBS. A small meta-analysis suggests
prevalence of coeliac disease in patients diagnosed with IBS is
around 4 times the population rate [10], but there are no large
cohort studies considering this. Incidence rates of IBD and CRC
in patients with IBS have previously been calculated, with
estimates of IBD incidence between 8 [11] and 16 [12] times
that in the general population and no increased incidence of CRC
[12]. These studies, however, have short follow up periods and in
one the study population were service personnel, unlikely to be a
representative sample. Consequently, changes in risk of diagnoses
of IBD, coeliac disease and CRC over a long time period after a
diagnosis of IBS in a general population has not been studied and
variations in risk by age and sex are unknown. A community based
study followed 112 patients with IBS for a median of 29 years after
diagnosis to assess incidence of organic gastrointestinal disease and
found 3.5% were subsequently diagnosed with gastrointestinal
cancer between 13 and 30 years later. They did not compare this
to diagnoses in the general population to assess any excess risk and
there was no incident IBD or coeliac disease [13].
We have therefore conducted a study within contemporary UK
practice to determine the risk of diagnosis of coeliac disease, IBD
and CRC over 15 years following IBS diagnosis and determined
variation in risk according to time since diagnosis, age and sex. To
aid better clinical decision making we have determined risk in
absolute as well as relative terms.
Methods
Data were taken from the Clinical Practice Research Datalink
(CPRD). CPRD is an anonymised longitudinal dataset of over 13
million medical records from over 640 primary care practices
across the UK, collected prospectively from routine care since
1987 [14,15]. Almost two thirds of the practices are linked to the
National Health Service Hospital Episode Statistics (HES),
providing secondary care data from NHS hospitals in England
since 1989 [15,16]. Only practices with HES linked CPRD
records and individuals with records audited to acceptable
research quality [14] were included. This project was given ethical
approval by the CPRD Independent Scientific Advisory Commit-
tee (protocol approval reference 12_047R) and all data was
anonymised and de-identified by CPRD before release to us and
prior to analysis. For this study we drew data from the July 2012
version of CPRD. All selections and definitions listed below were
made using code lists available on request from the corresponding
author.
IBS population
People with IBS were identified by a Read code for IBS in their
CPRD record for either a clinical or referral episode. Validity of
these codes has been established by Huerta et al who contacted the
primary care physicians of patients with Read codes consistent
with incident IBS in CPRD and found records to be accurate in
77% of cases [17]. The purpose of the study is to examine the
correlates of a GP diagnosis of IBS rather than those of the Rome
criteria [2], so our inability to validate our code lists against these
criteria is of limited importance. This study was only concerned
with diagnoses of coeliac disease, IBD or CRC after an initial
diagnosis of IBS, so any patients with these diagnoses before an
IBS diagnosis were excluded, as were patients aged under 18 or
over 75 years at diagnosis. We considered the earliest date
associated with an IBS episode to be the date of diagnosis, and this
was when the patient entered the study. IBS diagnoses were
considered incident when this date was at least one year after the
patient began contributing prospective data to CPRD (a previ-
ously validated strategy) [18]. 112854 cases of IBS met these
criteria. Exit from the study was the earliest of date of death, date
of transferring out of the practice or last date of data collection for
the CPRD from that practice.
Control population
Individuals were eligible to be controls if they had no recorded
diagnosis of IBS and no prescription for peppermint oil or the
spasmolytics Meberverine and Alverine (three medications pre-
scribed for treatment of IBS and rarely for other conditions). As
the controls, by definition, had no IBS diagnosis they had no
diagnosis date to define entry to study and start of follow up. To
allow for this and provide a date with which to match them to
cases a pseudodiagnosis date was generated. Each potential control
was allocated a pseudodiagnosis date randomly during the period
they were alive and contributing data to CPRD, and controls were
frequency matched [19] by sex, and age at diagnosis/pseudo-
diagnosis in 3 age bands (18–29, 30–49, and 50–75). The control
population was generated five times the size of the case population
to provide enough power to detect differences in incidence and
conduct the stratified analyses [20]. Exit was defined in the same
way as in cases.
Defining other gastrointestinal diagnoses
All coeliac disease [21] and IBD [22] cases were defined as
previously described as individuals who had at least one clinical
episode with a Read code for coeliac disease or IBD in their
CPRD record. CRC [23] cases were identified through either a
clinical episode in the CPRD with a CRC Read term code or an
episode in the linked HES records with an appropriate ICD-10
code. Incident diagnoses were defined as those where the first
episode with an appropriate code occurred after the IBS diagnosis
(or pseudodiagnosis) date.
Statistical analysis
All patients with prevalent coeliac disease, IBD or CRC at date
of IBS diagnosis (or pseudodiagnosis), or diagnosed on the same
day were excluded from the analysis of incidence of that disease.
Patients without an IBD clinical code with prescriptions for
mesalazine, azathioprine, mecaptopurine and rectal steroids are
likely to have these therapies for IBD so were also excluded from
IBD incidence analysis. Incidence rates of coeliac disease, IBD and
CRC were calculated by dividing the number of cases occurring
by the person years at risk and are presented per 10000 person
years with 95% confidence intervals (CI) and calculated over
whole follow-up and after excluding the 1st year. Nelson-Aalen
cumulative hazard plots were generated for each condition
separately. Poisson regression was used to estimate rate ratios
and 95% CIs for the purposes of comparing the IBS and control
cohorts. Likelihood ratio tests were used to check whether
interactions exist between the incidence rates of each condition
and age, calendar time, sex and smoking, which might suggest
subgroups in which particular care should be taken to check for
alternative diagnoses. A p value of less than 0.05 was taken to
indicate evidence of an interaction. Rates were stratified by
current age (in bands 18–29, 30–49, 50–74, 75 and older) and
calendar time since diagnosis and compared using rate ratios. As
there were few coeliac disease and IBD events in those aged over
75 years, this age group was combined with those aged 50 to 74
years for these analyses. Conversely, there were few CRC events in
those aged 18 to 29 years so this group was combined with those
Incidence of Organic GI Disease following IBS Diagnosis
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aged 30 to 49 years. For the absolute rate differences, the same age
groupings were used across the three diseases to allow direct
comparison. The IBD group was also stratified into disease type
(Crohn’s disease, ulcerative colitis and unspecified) to assess any
differences.
Results
Cohort demographics
There were 112854 cases of incident IBS aged between 18 and
75 years at diagnosis who contributed 733583 person-years of
follow-up. Follow-up was more than five years for 61562 (55%),
more than ten years for 27860 (25%) and 9224 cases (8%) had
more than 15 years follow-up. To these, 546903 controls were
frequency matched contributing 1990165 person-years of follow-
up, with 149321 followed up for more than 5 years (27%) and
49368 for more than ten years (9%). The mean age at diagnosis of
IBS (or pseudodiagnosis) was 42.9 years in the cases and 42.8 years
in the controls (table 1). Figures 1, 2 and 3 shows the cumulative
incidence of coeliac disease, IBD and CRC in patients following
their IBS diagnosis over 15 years of follow-up compared to
controls showing a steep increase in organic diagnoses in the first
year or so after IBS diagnosis and then generally proportional
risks. Combined, the overall cumulative incidence of being
diagnosed with one of these conditions after IBS was 3.7%,
compared to 1.7% in controls.
Coeliac disease
During follow up 395 IBS cases and 299 controls were
diagnosed with coeliac disease. Median time to coeliac disease
diagnosis was 2.6 years following IBS diagnosis (IQR 0.7 to 6.8
years) and 3.5 years following pseudodiagnosis (IQR 1.31 to 7.07
years). Mean age at diagnosis of coeliac disease was 49 years in IBS
patients and 53 years in controls.
Overall incidence of coeliac disease was 5.26 per 10000 person-
years in IBS patients (95% CI 4.77 to 5.81) and 1.49 per 10000
person-years (95% CI 1.33 to 1.67) in controls, with a cumulative
incidence of 0.7% of IBS patients after 15 years and 0.25% of
controls (figure 1). The cumulative incidence of coeliac disease in
IBS patients continues to diverge from that of controls even after
15 years (figure 1).
In IBS patients, an absolute rate difference of 4 extra coeliac
disease diagnoses per 10000 person-years was seen over total
follow-up compared to controls. The overall incident rate ratio
(IRR) was 3.54 (95% CI 3.04 to 4.11), falling to 2.84 when the
year after diagnosis was excluded (95% CI 3.38 to 3.38). Table 2
shows how the IRR varies with time since diagnosis and by the age
of the patient. In the first 6 months after IBS diagnosis the
incidence of coeliac disease was between 9.4 and 26.1 times higher
than in controls, but this fell to between 2 and 7 times higher
thereafter. This is reflected in the absolute rate difference (table 3)
falling from between 12 to 17 additional coeliac disease diagnoses
per 10000 person years in the first six months to a consistent excess
after one year of between 3 and 4 cases per 10000 person years in
those aged under 75 years. There was no significant increase in
those aged over 75 years.
There was no statistically significant difference in the incidence
of coeliac disease in men and women and no interaction between
coeliac disease incidence and sex or smoking status.
Figure 1. Cumulative frequency of coeliac disease in patients
with IBS following IBS diagnosis compared to controls.
doi:10.1371/journal.pone.0106478.g001
Figure 2. Cumulative frequency of IBD in patients with IBS
following IBS diagnosis compared to controls.
doi:10.1371/journal.pone.0106478.g002
Figure 3. Cumulative frequency of coeliac disease CRC in
patients with IBS following IBS diagnosis compared to
controls.
doi:10.1371/journal.pone.0106478.g003
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IBD
During follow-up 1184 IBS patients and 569 controls were
diagnosed with IBD. The median time to diagnosis of IBD from
IBS diagnosis was 1.7 years (IQR 0.49 years to 4.6 years) and 3.1
years (IQR 1.3 to 6.4 years) from pseudodiagnosis in controls. The
mean age at IBD diagnosis was 45 years in IBS patients and 52
years in controls.
Overall incidence of IBD was 16.12 per 10000 person-years in
IBS patients (95% CI 15.23 to 17.07) and 2.85 per 10000 person-
years (95% CI 2.63 to 3.10) in controls. The cumulative incidence
of IBD after 15 years was 1.9% of IBS patients and 0.5% of
controls and the rates continue to diverge even after 15 years
(figure 2).
Over the total follow-up there was an absolute rate difference of
13 extra cases of IBD per 10000 person-years in IBS patients
compared to controls. The overall IRR was 5.63 (95% CI 5.11 to
6.24), which fell to 3.98 (95% CI 3.54 to 4.45) after the first year
following IBS diagnosis was excluded. In the first 6 months after
IBS diagnosis incidence of IBD in IBS was between 16.8 and 24.5
times that seen in the controls depending on age (table 4), an
absolute rate difference of between 40 and 66 extra cases of IBD
per 10000 person years (table 3). After 5 years, incidence of IBD in
IBS patients remained between 2.6 to 5.0 times higher than in
controls, with between 3 and 13 additional IBD diagnoses per
10000 person years depending on age.
There was a significant interaction between incidence of IBD
and current patient age (p ,0.001). Whilst the risk ratios were not
statistically significantly different according to age, because the
underlying population incidence of IBD is higher in young people,
the absolute rate difference in IBS compared to controls is
significantly higher in those aged under 30 years after the first year
following IBS diagnosis. There was a statistically significant
interaction (p,0.001) between IBD incidence and sex. Overall
incidence of IBD in men with IBS was 20.3 per 10000 patient
years (95% CI 18.4 to 22.4) and 14.6 per 10000 patient years (95%
CI 13.6 to 15.6) in women, but there was no statistically significant
difference according to sex in controls. Stratification by IBD type
showed no significant difference in any of the analyses. There was
no interaction between the smoking status of IBS cases and
controls and the incidence of IBD in each group.
CRC
During follow up 708 people with IBS and 1148 controls were
diagnosed with CRC. The median time from diagnosis of IBS to
CRC diagnosis was 1.9 years (IQR 0.4 to 6.6 years), and 4.2 years
in controls (IQR 1.8 to 7.9 years). Mean age at diagnosis was 63
years in IBS patients and 67 years in controls.
Overall incidence of CRC was 9.38 per 10000 person-years in
IBS patients (95% CI 8.71 to 10.09) and 5.72 per 10000 person-
years (95% CI 5.40 to 6.06) in controls. The cumulative incidence
of CRC in IBS patients was 1.2% after 15 years and 1% in
controls and rates began to converge soon after IBS diagnosis
(figure 3).
Over the total follow-up there was an absolute rate difference of
4 extra CRCs per 10000 patient years in IBS patients compared to
controls with an overall IRR of 1.64 (95% CI 1.49 to 1.80), which
fell to 1.03 (95% CI 0.93 to 1.16) after the first year following IBS
diagnosis was excluded, not statistically significantly different from
the rate in the controls. In the first 6 months after IBS diagnosis
the incidence of CRC was between 4 and 41 times higher than in
controls depending on age, falling to between 1.3 and 1.7 times
higher after one year (table 5). Patients who were aged under 30
only had an increased incidence of CRC in the first 6 months
following IBS diagnosis. After this period and in those aged over
75 years at any time there was no significant increase in incidence
of CRC compared to controls (table 3). For those aged 30 to 74,
after 5 years there was no statistically significant difference in CRC
incidence compared to controls, there is even a trend towards
lower rates in patients with IBS.
There was a statistically significant interaction (p = 0.005)
between CRC incidence and sex. Overall incidence of CRC in
men with IBS was 14.9 per 10000 patient years (95% CI 13.3 to
16.6) and 7.3 per 10000 patient years (95% CI 6.7 to 8.1) in
women. In controls, men still had higher rates but the difference
was less (7.6 and 5.0 per 10000 patient years respectively). There
was no interaction with smoking.
Discussion
During the 15 years following a diagnosis of IBS, cumulative
incidence of coeliac disease was 0.7%, 1.8% for IBD and 1.2% for
CRC. This means the overall cumulative incidence of IBS patients
receiving a diagnosis of at least one of these conditions was 3.7%,
an absolute excess of 2.0% compared to people without IBS. In all
three conditions, peak excess incidence was in the first 6 months
following IBS diagnosis, followed by a marked drop after one year.
Median time to each organic diagnosis was also less than three
years following IBS diagnosis. This suggests that much of the
excess incidence of organic gastrointestinal disease occurs during
the diagnostic work-up, in these cases the IBS code does not reflect
a final diagnosis but rather it is part of the clinical pathway to
obtaining a final organic diagnosis. The most concerning
differential diagnosis for physicians and patients is probably
CRC [7] and our study has reassuringly shown that incidence is no
higher than the general population in young or elderly patients,
and for those aged 30 to 74 years the excess incidence is very low
after one year and disappears after 5 years following IBS diagnosis.
For coeliac disease and IBD the incidence remains higher in IBS
patients than in controls at all ages, even after ten years with an
IBS diagnosis, but the absolute excess risk although statistically
significant, is small in absolute terms.
Table 1. Frequency and percentage of patients and controls stratified by age at IBS diagnosis and sex.
Age at IBS diagnosis Total IBS population Control population
Cases (%) Controls (%) Male (%) Female (%) Male (%) Female (%)
18–29 26954 (23.88) 126586 (23.15) 5883 (21.83) 21071 (78.17) 27398 (21.64) 99188 (78.36)
30–49 49121 (43.53) 246339 (45.04) 14141 (28.79) 34980 (71.21) 70635 (28.67) 175704 (71.33)
50–75 36779 (32.59) 173978 (31.81) 11478 (31.21) 25301 (68.79) 53322 (30.65) 120656 (69.35)
Total 112854 546903 31502 (27.91) 81352 (72.09) 151355 (27.67) 395.548 (72.33)
doi:10.1371/journal.pone.0106478.t001
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Table 2. Incidence rate of coeliac disease after IBS diagnosis and the incidence rate ratio.
Current
age
Time since IBS
diagnosis IBS population Control population
Rate
ratio 95% CI
n { % ` N {{
Person time
(years)
Incidence rate
(per 10000 person years) 95% CI n { % ` N {{
Person time
(years)
Incidence rate
(per 10000 person years) 95% CI
18–29 0–6 months 20 0.07 26976 12704 15.7 10.2–24.4 3 0.00 126742 49777 0.6 0.2–1.9 26.1 7.8–87.9
6–12 months 9 0.04 23812 11128 8.1 4.2–15.5 3 0.00 80991 34616 0.9 0.3–2.7 9.3 2.5–34.5
1–5 years 23 0.11 20707 49000 4.7 3.1–7.0 7 0.01 59342 104460 0.7 0.3–1.4 7.0 3.0–16.3
5–10 years 6 0.10 6134 12943 4.6 2.1–10.3 2 0.02 9654 19058 1.0 0.3–4.2 4.4 0.9–21.9
10 years to end
of follow-up
0 0.00 467 400 0.0 - 1 0.14 736 629 15.9 2.2–110.0 - -
30–49 0–6 months 46 0.09 50158 23983 19.1 14.4–25.6 19 0.01 251595 108719 1.7 1.1–2.7 11.0 6.4–18.7
6–12 months 15 0.03 47953 22843 6.6 4.0–10.9 17 0.01 199764 90184 1.9 1.2–3.0 3.5 1.7–7.0
1–5 years 59 0.12 50378 142459 4.1 3.2–5.3 60 0.03 178836 407334 1.5 1.1–1.9 2.8 2.0–4.0
5–10 years 39 0.13 30147 92047 4.2 3.1–5.8 29 0.05 62419 163736 1.8 1.2–2.5 2.4 1.5–3.9
10 years to end
of follow-up
9 0.08 11224 36409 2.5 1.3–4.8 6 0.04 15233 42967 1.4 0.6–3.1 1.8 0.6–5.0
50 and
older
0–6 months 23 0.06 37514 18078 12.7 8.5–19.1 11 0.01 177546 81018 1.4 0.8–2.5 9.4 4.6–19.2
6–12 months 11 0.03 36673 17671 6.2 3.4–11.2 13 0.01 157476 73446 1.8 1.0–3.0 3.5 1.6–7.9
1–5 years 55 0.13 41393 126085 4.4 3.3–5.7 63 0.04 161835 430279 1.5 1.1–1.9 3.0 2.1–4.3
5–10 years 44 0.13 32915 111267 4.0 2.9–5.3 38 0.04 91991 277990 1.4 1.0–1.9 2.9 1.8–4.5
10 years to end
of follow-up
36 0.18 19968 73768 4.9 3.5–6.8 27 0.07 37207 125851 2.1 1.5–3.1 2.3 1.4–3.7
Incident rate ratios in bold are statistically significant and have a p-value ,0.05.
{
n is the number of people diagnosed with coeliac disease within the stratum;
`% is the proportion that these diagnoses represent within the stratum;
{{N is the total number of patients contributing time to the stratum. The rates are split by time since IBS was diagnosed and the current age of the patient. This means, for example, that the risk of coeliac disease for someone who
is 34 and was diagnosed with IBS 6 years ago can be seen as 2.8 times greater than someone without IBS.
doi:10.1371/journal.pone.0106478.t002
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Table 3. Absolute incidence rate difference between IBS cases and controls for each disease stratified by current age and time since IBS diagnosis.
Current age
Time since IBS
diagnosis Coeliac disease IBD CRC
Absolute rate difference
(per 10000 person years) 95% CI
Absolute rate difference
(per 10000 person years) 95% CI
Absolute rate difference
(per 10000 person years) 95% CI
18–29 0–6 months 15.10 4.83–16.45 66.25 51.66–80.84 3.14 0.06–6.23
6–12 months 7.20 0.43–9.22 38.26 26.20–50.33 0.90 20.86–2.66
1–5 years 4.00 1.46–4.71 18.51 14.35–22.67 20.57 21.03– 20.12
5–10 years 3.60 20.87–6.51 12.62 5.26–19.99 - -
10 years to end
of follow-up
- - 9.62 24.99–6.91 - -
30–49 0–6 months 17.40 9.34–19.38 55.21 45.45–64.98 17.44 10.07–22.80
6–12 months 4.70 1.66–7.98 32.39 24.61–40.16 3.93 1.18–6.67
1–5 years 2.60 1.34–3.35 11.73 9.72–13.74 0.94 0.18–1.69
5–10 years 2.40 0.13–2.60 4.87 2.83–6.91 0.05 20.79–0.89
10 years to end
of follow-up
1.10 20.51–3.05 5.88 2.49–9.27 20.26 21.96–1.44
50–74 0–6 months 11.7 6.4–16.9 39.52 29.88–49.16 83.46 69.09–97.84
6–12 months 4.7 0.8–8.5 16.93 10.09–23.78 24.65 15.56–33.76
1–5 years 3.1 1.8–4.4 9.75 7.61–11.90 2.69 0.50–4.89
5–10 years 2.7 1.3–4.0 6.49 4.40–8.59 0.37 24.85–2.59
10 years to end
of follow-up
2.8 0.8–4.8 3.94 1.57–6.31 21.09 24.14–1.95
75 and older 0–6 months - - - - 94.64 2939.23–496.49
6–12 months - - - - - -
1–5 years 20.8 23.9–2.3 6.14 22.85–15.14 24.59 217.97–0.78
5–10 years 2.0 20.1–4.9 3.21 21.79–8.21 4.58 26.34–15.54
10 years to end
of follow-up
2.4 21.5–6.3 5.06 0.05–10.10 21.76 212.01–8.49
Rates in bold are statistically significant with a p-value ,0.05 The absolute rate difference indicates how many additional people would be expected to be diagnosed with each condition in a group with IBS, rather than the
proportional difference that is presented in the rate ratio measure.
doi:10.1371/journal.pone.0106478.t003
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Table 4. Incidence rate of IBD after IBS diagnosis and the incidence rate ratio.
Current
age
Time since
IBS diagnosis IBS population Control population
Rate
ratio 95% CI
n { % ` N {{
Person time
(years)
Incidence rate
(per 10000
person years) 95% CI n { % ` N {{
Person time
(years)
Incidence rate
(per 10000
person years) 95% CI
18–29 0–6 months 87 0.32 26789 12596 69.1 56.0–85.2 14 0.01 126414 49652 2.8 1.7–4.8 24.5 13.9–43.1
6–12 months 45 0.17 26578 11010 40.9 30.5–54.7 9 0.01 80793 34527 2.6 1.4–5.0 15.7 7.7–32.1
1–5 years 100 0.49 20472 48266 20.7 17.0–25.2 23 0.04 59180 104129 2.2 1.5–3.3 9.4 6.0–14.8
5–10 years 20 0.33 6027 12669 15.8 10.2–24.5 6 0.06 9607 18946 3.2 1.4–7.1 5.0 2.0–12.4
10 years to end
of follow–up
1 0.22 458 389 25.7 3.6–182.6 1 0.14 729 621 16.1 2.3–114.3 1.6 0.1–25.5
30–49 0–6 months 137 0.28 49455 23624 58.0 49.1–68.6 30 0.01 250082 108046 2.8 1.9–4.0 20.9 14.1–31.0
6–12 months 78 0.17 47191 22459 34.7 27.8–43.4 21 0.01 198503 89613 2.3 1.5–3.6 14.8 9.2–24.0
1–5 years 195 0.39 49500 139731 14.0 12.1–16.1 90 0.05 177732 404694 2.2 1.8–2.7 6.3 4.9–8.1
5–10 years 72 0.24 29513 89988 8.0 6.4–10.1 51 0.08 62018 162675 3.1 2.4–4.1 2.6 1.8–3.7
10 years to end
of follow–up
30 0.27 10945 35455 8.5 5.9–12.1 11 0.07 15130 42675 2.6 1.4–4.7 3.3 1.7–6.6
50 and older 0–6 months 74 0.20 37117 17689 41.8 33.3–52.5 20 0.01 177232 80144 2.5 1.6–3.9 16.8 10.2–27.5
6–12 months 34 0.09 36285 17272 19.7 14.1–27.5 22 0.01 157305 72650 3.0 2.0–4.6 6.5 3.8-11.1
1–5 years 160 0.37 43224 122965 13.0 11.1–15.2 147 0.09 168697 425404 3.5 2.9–4.1 3.8 3.0–4.7
5–10 years 101 0.30 34179 108384 9.3 7.7–11.3 89 0.09 97062 274856 3.2 2.6–4.0 2.9 2.2–3.8
10 years to end
of follow-up
50 0.25 19916 71811 7.0 5.3–9.2 35 0.09 39420 124469 2.8 2.0–3.9 2.5 1.6–3.8
Incident rate ratios in bold are statistically significant and have a p-value ,0.05.
{
n is the number of people diagnosed with IBD within the stratum;
`% is the proportion that these diagnoses represent within the stratum;
{{N is the total number of patients contributing time to the stratum. The rates are split by time since IBS was diagnosed and the current age of the patient. This means, for example, that the risk of IBD for someone who is 34 and
was diagnosed with IBS 6 years ago can be seen as 2.6 times greater than someone without IBS.
doi:10.1371/journal.pone.0106478.t004
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Table 5. Incidence rate of CRC after IBS diagnosis and the incidence rate ratio.
Current
age
Time since
IBS diagnosis IBS population Control population
Rate
ratio 95% CI
n { % ` N {{
Person time
(years)
Incidence rate
(per 10000
person years) 95% CI n { % ` N {{
Person time
(years)
Incidence rate
(per 10000
person years) 95% CI
18–49 0–6 months 47 0.06 77254 36747 12.8 13.3–24.1 5 0.00 378738 158672 0.3 0.2–1.1 40.6 15.4–98.4
6–12 months 11 0.02 71887 34035 3.2 2.4–8.1 4 0.00 281067 124949 0.3 0.2–1.2 10.1 3.1–31.4
1–5 years 26 0.04 71235 191965 1.4 1.2–2.7 42 0.02 238462 512415 0.8 0.6–1.2 1.7 1.2–3.4
5–10 years 10 0.03 36389 105387 0.9 0.6–2.0 17 0.02 72164 183078 0.9 0.6–1.7 1.0 0.5–2.3
10 years until
end of follow-up
5 0.04 11746 36993 1.4 0.6–3.3 7 0.04 16002 43691 1.6 0.8–3.4 0.8 0.3–2.6
50–74 0–6 months 168 0.45 37387 17891 93.9 80.7–110.0 84 0.05 177109 80459 10.4 8.4–12.9 9.0 6.9–11.7
6–12 months 60 0.17 36053 17254 34.8 27.0–44.8 73 0.05 155574 72141 10.1 8.0–12.7 3.4 2.4–4.8
1–5 years 142 0.35 40362 117682 12.1 10.2414.2 380 0.24 158585 405398 9.4 8.5–10.4 1.3 1.1–1.6
5–10 years 87 0.29 30112 96815 9.0 7.3–11.1 209 0.25 84429 242501 8.6 7.5–9.8 1.0 0.8–1.3
10 years to end
of follow-up
52 0.32 16394 60034 8.7 6.6–11.4 98 0.31 31509 100508 9.8 8.0–11.9 0.9 0.6–1.2
75 and older 0–6 months 1 0.27 369 81 123.3 17.4–880.0 1 0.06 1551 349 28.7 4.0–200.0 4.3 0.3–68.8
6–12 months 0 0.00 787 280 - - 3 0.10 3011 1104 27.2 8.8–84.9 - -
1–5 years 19 0.53 3556 7503 25.3 16.2–39.7 70 0.61 11481 23397 29.9 23.7–37.4 0.8 0.5–1.4
5–10 years 44 0.89 4935 13762 32.0 23.8–43.0 94 0.70 13344 34311 27.4 22.4–33.5 1.2 0.8–1.7
10 years to end
of follow-up
31 0.78 3971 13423 23.1 16.2–32.8 61 0.75 8110 24542 24.9 19.3–32.0 0.9 0.6–1.4
Incident rate ratios in bold are statistically significant and have a p-value ,0.05.
{
n is the number of people diagnosed with CRC within the stratum;
`% is the proportion that these diagnoses represent within the stratum;
{{N is the total number of patients contributing time to the stratum. The rates are split by time since IBS was diagnosed and the current age of the patient. This means, for example, that the risk of CRC for someone who is 34 and
was diagnosed with IBS 6 years ago can be seen as being the same (1.0) someone without IBS.
doi:10.1371/journal.pone.0106478.t005
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A major strength of our study is that it is the largest study of its
type yet conducted, with power to consider not only the overall
incidence rates, but to allow stratification by the individuals’ sex,
current age and time since IBS diagnosis. Such stratification allows
us to more clearly define which of these organic gastroenterolog-
ical conditions individual patients are at greater risk of. For
example, a young male IBS patient is far more likely to have IBD
than an elderly female one. A second strength is that the length of
follow-up is greater than previous studies. Shorter studies are likely
to be biased by the higher rates we have shown in the first 12
months, probably related to the diagnostic work-up for IBS. Our
study adds 12 years of follow-up to the findings of Garcia-
Rodriguez et al [12], allowing assessment of how incidence of
organic disease changes over time since IBS diagnosis. Since most
IBS diagnoses are made among those under 50 years such
prolonged follow up is of particular importance. A further strength
is that all subjects are taken from primary care. Since IBS is mainly
diagnosed and managed within primary care, and recommenda-
tions suggest that this is optimal practice [2–4], our study design
allows accurate assessment of the potential for missed organic
gastrointestinal disease in patients treated in a typical manner
rather than by those with a specialist interest in IBS. Many studies
of IBS focus only on patients who attend secondary care who are
likely to be systematically different to the majority of IBS patients
who never consult secondary care. Studying all IBS patients
identified within primary and secondary care removes this bias.
Controls were defined as having neither a clinical episode with an
IBS Read code attached nor a recorded prescription for
peppermint oil, Mebeverine or Alverine. Although people with
IBS take many medications, these are the only medications used
almost exclusively in IBS. Excluding everyone who had used any
medication potentially for IBS would more completely avoid
misclassification of controls but would exclude everyone ever
prescribed anti-depressants, anxiolytics, laxatives or anti-diarrhoe-
al agents, potentially selecting a control population with better
health than the general population. Studies within the community
suggest that around 50-70% of people with symptoms consistent
with IBS never seek medical attention [24]. Thus some
undiagnosed IBS will exist amongst controls but this should not
invalidate our study since its aim is to address the incidence of
organic gastrointestinal disease in patients recorded as having IBS
within primary care.
Inaccurate coding presents a potential limitation. There is no
definitive investigation finding to use as a gold standard for code
list validation in IBS. For this study question, however, the lack of
truly independent validation is less of a concern because the
interest is in organic gastrointestinal diagnoses made in patients
labelled as having IBS and consequently treated as such. Previous
studies have shown coding of IBS within CPRD to be valid when
compared to General Practitioner’s opinion. Only 1% of coded
incident IBS and 16% of prevalent IBS were not confirmed as IBS
by the GP [25]. Similarly, 92% of IBD codes [22], over 90% of
CRC codes [23] and a similar proportion of coeliac disease codes
[26] have been shown to be valid. There is no reason to suppose
that coding errors for events with CRC, IBD or coeliac codes are
systematically different between IBS patients and controls, so this
should not introduce any bias. These data do not allow assessment
of how closely the Rome criteria were employed in establishing the
IBS diagnosis or how closely the NICE clinical guidelines were
followed. Differences in incidence of organic gastrointestinal
disease according to diagnostic work up warrants further study.
A further limitation of our study is that we have not considered the
impact of confounding by socioeconomic status which might be
associated with the risk of coeliac disease or IBD but is not
significantly associated with IBS and so we think appreciable
confounding unlikely [24,27].
This is the first large primary care based cohort study to
consider the incidence of coeliac disease in patients diagnosed with
IBS. We found the cumulative incidence of coeliac disease was
0.7% of the incident IBS cases after 15 years, just under three
times that in the controls. Our results are lower than the outcome
of a systematic review of coeliac disease in IBS but show a similar
increase compared to the general population. The review reported
a pooled estimate of coeliac disease prevalence as 4% among 2278
IBS patients, four times that seen in controls [10]. One reason our
cumulative incidence rate is lower may relate to as yet
undiagnosed coeliac disease in our IBS cases. Also we have
measured the cumulative incidence over time rather than
prevalence. A study using an earlier version of CPRD in 2000
looked at the rate of diagnosis of IBD and CRC [12]. Then they
had just under 3000 IBS cases and included only 5 years following
IBS diagnosis. During this period they also saw initially high rates
of IBD and CRC fall in the first year. They reported a crude
incidence of 26.2 CRCs diagnosed per 10000 patient years [12],
(considerably higher than we report over the complete follow-up
now available, but similar to the incidence we found in the early
follow-up period), and no overall excess compared to controls.
They found an overall crude incidence of IBD of 17.8 cases per
10000 person years, 16 times the rate in controls [12] which is
similar to our finding. Over their total follow-up they saw no
reduction in the rate of IBD, however with increased follow-up we
have shown that incidence does decrease over time, but still
remains higher than in the general population. A US database
study of IBS in over 9000 military personnel looked specifically at
the risk of being diagnosed with IBD [11]. The average follow-up
was 3.6 years and they found the rate of IBD diagnosis was 8 times
higher than in the general population. The slightly lower excess of
IBD in this study may reflect differences in medical practice
between the USA and UK, but may also reflect a military
population being relatively healthier than the population seen in
routine UK primary care. Median time from IBS diagnosis to IBD
diagnosis was 2.1 years, similar to our findings [11]. A low
incidence (1.9%) of organic colonic disease was also found in a
study reviewing colonoscopy outcomes in patients having the
procedure to confirm IBS [28], with incidence of IBD and CRC
not significantly increased compared to healthy controls [28].
The clinical implications here are that a clinical diagnosis of IBS
in general practice is highly unlikely to lead to a serious
gastrointestinal diagnosis in the following 15 years. Thus patients
can be reassured, particularly after the relatively higher risk period
immediately after IBS diagnosis has passed. This is especially true
for CRC where a trend towards a reduced rate in IBS patients
might be explained by IBS patients receiving a colonoscopy during
their diagnostic work-up and any lesions being detected at that
point. For coeliac disease and IBD, however, the incidence in IBS
patients remains above that in the general population throughout.
Previous analysis has suggested serological testing for coeliac
disease would be cost-effective for all IBS patients at the time of
diagnosis [29]. Our results will allow greater accuracy in
estimating the parameters of the model underlying this analysis
but they do not tell us the value of repeated testing for coeliac
disease. As the absolute excess rate of coeliac disease is very small
we cannot rule out the possibility that it reflects patients who are
seronegative for coeliac disease when diagnosed with IBS
seroconverting later on. Similarly for IBD, a recent report shows
that over a quarter of patients with endoscopic remission of IBD
complain of IBS-like symptoms [30], and this alongside findings
that mesalazine may resolve symptoms in some IBS patients [31]
Incidence of Organic GI Disease following IBS Diagnosis
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could support a suggestion that symptoms compatible with IBS
might in some instances reflect clinically undetectable IBD. Hence
we cannot rule out the value of repeated investigation for this
diagnosis either. Since the overall risk is very low, however, we
believe any repeat investigation should be individually assessed.
In summary, our study shows that the vast majority of people
who receive an organic diagnosis following a recording of IBS
within primary care do so in the first year following their IBS
diagnosis, which is clearly part of the diagnostic work up process.
Five years after an IBS diagnosis, compared to people without IBS,
there remains a small, but nonetheless important and statistically
significant, excess risk of organic diagnoses. Overall our findings
provide reassurance that non-specialists, especially in primary care
who see most people diagnosed with IBS, are unlikely to be
missing an organic condition in the majority of their patients.
However younger IBS patients, particularly males, have a
persistently increased risk of IBD, and patients of all ages still
have a slight increased risk of having coeliac disease. This suggests
that current guidelines suggesting avoidance of universal referral
for these patients are appropriate.
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